Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2025 07:30 ET | Source: Attovia Therapeutics, Inc.

Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept

Series C round led by Deep Track Capital with participation from additional new and existing investors Financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and...
January 23, 2025 07:30 ET | Source: Attovia Therapeutics, Inc.

Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus

ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug...
October 15, 2024 07:30 ET | Source: Attovia Therapeutics, Inc.

Attovia Therapeutics Appoints Chief Financial Officer

FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and...
July 09, 2024 07:30 ET | Source: Attovia Therapeutics, Inc.

Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of...
May 09, 2024 07:30 ET | Source: Attovia Therapeutics, Inc.

Attovia Therapeutics Raises $105 Million Oversubscribed Series B Financing Led by Goldman Sachs Alternatives

-- Proceeds support advancing Attovia’s lead programs through initial clinical readouts, expanding its pipeline, and ongoing development of the ATTOBODY™ platform -- Financing led by Goldman Sachs...
March 26, 2024 07:00 ET | Source: Attovia Therapeutics, Inc.

Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards

-- Hubert Chen, accomplished drug developer and pharma executive, joins as Chief Medical Officer -- Industry veterans and leading academic experts joined Attovia’s Clinical and Scientific...
February 08, 2024 07:30 ET | Source: Attovia Therapeutics, Inc.

Attovia Announces Second Tranche Closing of $60 Million Series A Financing and Highlights Progress Building a Best-in-Class Pipeline Leveraging the Attobody™ Platform

-- Financing supports building immunology and inflammation pipeline, advancing lead programs into the clinic and ongoing development of the Attobody platform -- Attovia’s lead programs include...
June 20, 2023 07:30 ET | Source: Attovia Therapeutics, Inc.; Alamar Biosciences, Inc.

Attovia Therapeutics Launches with $60 Million Series A Financing to Unlock Potential of Novel Biparatopic Nanobody Platform

Company Formed by Alamar Biosciences and Frazier Life Sciences Attobody™ Platform Generates Small Format Binders for Hard-to-drug Targets FREMONT, Calif. and MENLO PARK, Calif., June 20, 2023 ...